TOMS Capital Investment Management LP increased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 46.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 5,885,000 shares of the company's stock after acquiring an additional 1,870,000 shares during the period. Roivant Sciences comprises 2.5% of TOMS Capital Investment Management LP's portfolio, making the stock its 9th biggest position. TOMS Capital Investment Management LP owned about 0.81% of Roivant Sciences worth $69,620,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its stake in shares of Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after purchasing an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd purchased a new stake in Roivant Sciences in the 4th quarter valued at about $39,000. GAMMA Investing LLC grew its stake in Roivant Sciences by 57.0% in the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after acquiring an additional 1,288 shares in the last quarter. PNC Financial Services Group Inc. increased its position in shares of Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after acquiring an additional 1,507 shares during the period. Finally, Wells Fargo & Company MN raised its stake in shares of Roivant Sciences by 84.1% during the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company's stock valued at $89,000 after acquiring an additional 3,426 shares in the last quarter. Institutional investors own 64.76% of the company's stock.
Roivant Sciences Stock Performance
ROIV traded down $0.10 on Friday, hitting $11.48. The company had a trading volume of 8,767,529 shares, compared to its average volume of 5,516,819. The stock has a market capitalization of $8.19 billion, a price-to-earnings ratio of -76.53 and a beta of 1.25. The stock has a fifty day moving average price of $10.40 and a 200-day moving average price of $11.14. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last issued its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Analysts forecast that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
Insider Transactions at Roivant Sciences
In other news, COO Eric Venker sold 100,000 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $10.65, for a total transaction of $1,065,000.00. Following the sale, the chief operating officer now owns 896,869 shares in the company, valued at approximately $9,551,654.85. The trade was a 10.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now directly owns 163,264 shares of the company's stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,395,541 shares of company stock valued at $14,922,538. Corporate insiders own 7.90% of the company's stock.
Wall Street Analyst Weigh In
ROIV has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Monday, April 21st. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th.
Check Out Our Latest Report on Roivant Sciences
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Articles
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
